<DOC>
	<DOCNO>NCT02245828</DOCNO>
	<brief_summary>This double blind , randomize , placebo control , single multiple ascend dose study healthy subject . Safety evaluation include ( serious ) adverse event , vital sign , body weight lung function test . Blood sample Pharmacokinetics also draw specified timepoints .</brief_summary>
	<brief_title>A First Human Study Assess Safety , Tolerability Pharmacokinetics Single Multiple Ascending Doses QCC374</brief_title>
	<detailed_description />
	<criteria>1 . Written informed consent must obtain assessment perform . 2 . Healthy male female subject age 18 55 year age include , good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen . 3 . Weight least 50 kg body mass index ( BMI ) within range 18 32 kg/m2 . BMI = Body weight ( kg ) / [ Height ( ) ] 2 . 4 . Oxygen saturation ( O2 ) screen must ≥ 95 % room air . 5 . FEV1 ≥ 90 % predict . 1 . 1 . A history clinically significant ECG abnormality and/or orthostatic vital sign screen . 2 . History asthma reactive airway disease . 3 . Smokers anyone smoke within 5 year screen . Urine cotinine level ≥ 500 ng/mL . 4 . History malignancy organ system localize basal cell carcinoma skin , treat untreated within past 5 year , regardless whether evidence local recurrence metastasis . 5 . Women childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>healthy subject , inhale</keyword>
</DOC>